ANAVEX LIFE SCIENCES CORP.
AVXL · Biological Products, (No Diagnostic Substances) · 92.7M shares · +7%/yr ↑ dilution · EDGAR filings ↗
Grade
D44Clinical/early-stage biotech — Alzheimer's biotech, deep losses.
Strengths
- Liquidity — per balance sheet
Risks
- Pre-revenue, deep losses — per metrics
- Pre-revenue/clinical-stage — history of losses & need for capital per risk factors
- Binary clinical & funding risk — per 10-K
Notable findings
- Exec changeRecent 8-K item 5.02 8-K ↗
- Fund exitedNotable fund(s) exited this quarter: VANGUARD GROUP INC
- Strong balance sheetStrong balance sheet — $103M cash & investments
- Notable holderHeld by 5 notable fund(s): STATE STREET CORP, CITADEL ADVISORS LLC, GOLDMAN SACHS GROUP INC +2 more (as of 2026-03-31)
Key metrics
Return on equity
-48.9%
Return on assets
-44.7%
Tangible book value
$95M
Cash & investments
$103M
Insider transactions · last 18 months
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2025-09-11 | MISSLING CHRISTOPHER U | Option exercise | 188K | $5.04 |
| 2025-09-11 | MISSLING CHRISTOPHER U | Tax withheld | 145K | $9.58 |
| 2025-06-05 | Thomas Steffen | Option exercise | 50K | $1.76 |
| 2025-06-05 | Thomas Steffen | Tax withheld | 11K | $7.75 |
| 2025-03-24 | MISSLING CHRISTOPHER U | Option exercise | 500K | $0.92 |
| 2025-03-24 | MISSLING CHRISTOPHER U | Tax withheld | 282K | $9.63 |
All non-derivative Form 4 activity (SEC), newest first.
Clinical trials
| Trial | Title | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT06245213 ↗ | A Study of ANAVEX3-71 in Adults With Schizophrenia Schizophrenia | PHASE2 | Active Not Recruiting | 2025-06-30 |
| NCT04314934 ↗ | OLE of Phase 2b/3 Study ANAVEX2-73-AD-004 Alzheimer Disease | PHASE2/PHASE3 | Completed | 2024-06-14 |
| NCT04304482 ↗ | ANAVEX2-73 Study in Pediatric Patients With Rett Syndrome Rett Syndrome | PHASE2/PHASE3 | Completed | 2023-06-01 |
| NCT03790709 ↗ | ANAVEX2-73 for Treatment of Early Alzheimer's Disease Alzheimer Disease | PHASE2/PHASE3 | Completed | 2022-06-30 |
| NCT04575259 ↗ | OLE Study for Patients With Parkinson's Disease With Dementia Enrolled in Study ANAVEX2-73-PDD-001 Parkinson Disease Dementia | PHASE2 | Completed | 2022-05-31 |
| NCT03941444 ↗ | ANAVEX2-73 Study in Patients With Rett Syndrome Rett Syndrome | PHASE3 | Completed | 2021-09-30 |
| NCT04442945 ↗ | Phase 1 Study of ANAVEX3-71 Healthy | PHASE1 | Completed | 2021-09-30 |
| NCT02756858 ↗ | An Extension Study of ANAVEX2-73 in Patients With Mild to Moderate Alzheimer's Disease Alzheimer's Disease | PHASE2 | Completed | 2020-11-01 |
| NCT03758924 ↗ | Study of ANAVEX2-73 in Patients With Rett Syndrome Rett Syndrome | PHASE2 | Completed | 2020-10-30 |
| NCT03774459 ↗ | ANAVEX2-73 Study in Parkinson's Disease Dementia Parkinsons Disease With Dementia | PHASE2 | Completed | 2020-09-30 |
| NCT02244541 ↗ | Phase 2a Dose Finding, PK/PD and 12 Month Exploratory Efficacy Study of ANAVEX2-73 in Patients With Alzheimer's Disease Alzheimer's Disease | PHASE2 | Completed | 2015-11-01 |
Source: ClinicalTrials.gov (U.S. NIH) · active studies first.
Notable events (8-K)
| Date | Items | |
|---|---|---|
| 2026-06-26 | Other | filing ↗ |
| 2026-05-22 | Delisting noticeOtherExhibits | filing ↗ |
| 2026-05-15 | Exec/director change | filing ↗ |
| 2026-05-06 | Exec/director changeExhibits | filing ↗ |
| 2026-03-25 | OtherExhibits | filing ↗ |
| 2026-02-25 | Exec/director changeReg FDExhibits | filing ↗ |
| 2026-02-09 | ResultsExhibits | filing ↗ |
| 2025-11-25 | ResultsExhibits | filing ↗ |
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 8-K | 2026-06-26 | 2026-06-25 | 0001731122-26-000889 ↗ |
| 8-K | 2026-05-22 | 2026-05-20 | 0001731122-26-000781 ↗ |
| 8-K | 2026-05-15 | 2026-05-11 | 0001731122-26-000744 ↗ |
| 8-K | 2026-05-06 | 2026-04-30 | 0001731122-26-000678 ↗ |
| 8-K | 2026-03-25 | 2026-03-25 | 0001731122-26-000482 ↗ |
| 8-K | 2026-02-25 | 2026-02-20 | 0001731122-26-000305 ↗ |
| 10-Q | 2026-02-09 | 2025-12-31 | 0001731122-26-000200 ↗ |
| 8-K | 2026-02-09 | 2026-02-09 | 0001731122-26-000193 ↗ |
| 8-K | 2025-11-25 | 2025-11-25 | 0001731122-25-001591 ↗ |
| 10-K | 2025-11-25 | 2025-09-30 | 0001731122-25-001596 ↗ |
| 8-K | 2025-11-14 | 2025-11-14 | 0001731122-25-001536 ↗ |
| 10-Q | 2025-08-12 | 2025-06-30 | 0001731122-25-001105 ↗ |